Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
142 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anthrax - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H1 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape. Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 24 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively. Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Anthrax - Overview 7 Anthrax - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Anthrax - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Anthrax - Companies Involved in Therapeutics Development 25 Altimmune Inc 25 Aphios Corp 25 Aradigm Corp 26 AtralCipan 26 ContraFect Corp 27 Crestone Inc 27 Dynavax Technologies Corp 28 Emergent BioSolutions Inc 28 GlaxoSmithKline Plc 29 Green Cross Corp 29 Grifols SA 30 Hawaii Biotech Inc 30 iBio Inc 31 Merck & Co Inc 31 Microbiotix Inc 32 NanoBio Corp 32 Paratek Pharmaceuticals Inc 33 PaxVax Inc 33 Pfenex Inc 34 PharmAthene Inc 34 Planet Biotechnology Inc 35 Protein Potential LLC 35 ProThera Biologics Inc 36 Soligenix Inc 36 Syntiron LLC 37 Tetraphase Pharmaceuticals Inc 37 VLP Biotech Inc 38 Anthrax - Drug Profiles 39 anthrax (virus like particles) vaccine - Drug Profile 39 anthrax + plague vaccine - Drug Profile 40 anthrax vaccine - Drug Profile 41 anthrax vaccine - Drug Profile 43 anthrax vaccine - Drug Profile 44 anthrax vaccine - Drug Profile 45 anthrax vaccine - Drug Profile 46 anthrax vaccine - Drug Profile 47 Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 48 ARD-3100 - Drug Profile 49 AV-7909 - Drug Profile 53 BDM-I - Drug Profile 55 CF-306 - Drug Profile 58 CF-307 - Drug Profile 59 CF-308 - Drug Profile 60 ciprofloxacin hydrochloride - Drug Profile 61 CPN-1311 - Drug Profile 62 DPX-Anthrax - Drug Profile 63 DV-230 - Drug Profile 65 Epimerox - Drug Profile 66 EV-035 - Drug Profile 67 GC-1109 - Drug Profile 69 gepotidacin mesylate - Drug Profile 70 GREANX - Drug Profile 73 KKL-35 - Drug Profile 74 Marinus - Drug Profile 75 Monoclonal Antibody for Anthrax - Drug Profile 76 Monoclonal Antibody for Anthrax - Drug Profile 77 Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 78 Nasoshield - Drug Profile 79 omadacycline tosylate - Drug Profile 81 PBI-220 - Drug Profile 88 Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 90 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 91 Px-563L - Drug Profile 93 Px-563L Second Generation - Drug Profile 95 raxibacumab - Drug Profile 96 RiVax + SGX-204 - Drug Profile 97 rPA-01 - Drug Profile 98 RPA-563 - Drug Profile 99 Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 100 Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 101 Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 102 Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 103 Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 104 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 106 Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 107 solithromycin - Drug Profile 108 TP-271 - Drug Profile 121 Anthrax - Dormant Projects 123 Anthrax - Discontinued Products 126 Anthrax - Product Development Milestones 127 Featured News & Press Releases 127 Appendix 137 Methodology 137 Coverage 137 Secondary Research 137 Primary Research 137 Expert Panel Validation 137 Contact Us 137 Disclaimer 138
List of Tables
Number of Products under Development for Anthrax, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Anthrax - Pipeline by Altimmune Inc, H1 2017 Anthrax - Pipeline by Aphios Corp, H1 2017 Anthrax - Pipeline by Aradigm Corp, H1 2017 Anthrax - Pipeline by AtralCipan, H1 2017 Anthrax - Pipeline by ContraFect Corp, H1 2017 Anthrax - Pipeline by Crestone Inc, H1 2017 Anthrax - Pipeline by Dynavax Technologies Corp, H1 2017 Anthrax - Pipeline by Emergent BioSolutions Inc, H1 2017 Anthrax - Pipeline by GlaxoSmithKline Plc, H1 2017 Anthrax - Pipeline by Green Cross Corp, H1 2017 Anthrax - Pipeline by Grifols SA, H1 2017 Anthrax - Pipeline by Hawaii Biotech Inc, H1 2017 Anthrax - Pipeline by iBio Inc, H1 2017 Anthrax - Pipeline by Merck & Co Inc, H1 2017 Anthrax - Pipeline by Microbiotix Inc, H1 2017 Anthrax - Pipeline by NanoBio Corp, H1 2017 Anthrax - Pipeline by Paratek Pharmaceuticals Inc, H1 2017 Anthrax - Pipeline by PaxVax Inc, H1 2017 Anthrax - Pipeline by Pfenex Inc, H1 2017 Anthrax - Pipeline by PharmAthene Inc, H1 2017 Anthrax - Pipeline by Planet Biotechnology Inc, H1 2017 Anthrax - Pipeline by Protein Potential LLC, H1 2017 Anthrax - Pipeline by ProThera Biologics Inc, H1 2017 Anthrax - Pipeline by Soligenix Inc, H1 2017 Anthrax - Pipeline by Syntiron LLC, H1 2017 Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017 Anthrax - Pipeline by VLP Biotech Inc, H1 2017 Anthrax - Dormant Projects, H1 2017 Anthrax - Dormant Projects, H1 2017 (Contd..1), H1 2017 Anthrax - Dormant Projects, H1 2017 (Contd..2), H1 2017 Anthrax - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
